Researchers proposed a pre-lab computational ranking framework to triage safer and more effective RNA-lipid nanoparticle (LNP) formulations before experimental testing. The University of Catania team built a modular approach that evaluates candidate LNPs using virtual patient simulations and machine learning, alongside a mechanistic check against human single-cell data. The goal is to reduce attrition by prioritizing formulations with more favorable safety and efficacy properties earlier in development, rather than moving blindly into costly in vitro and in vivo screens. The work also reflects a growing regulatory-adjacent emphasis on early risk characterization for nucleic acid delivery systems, where formulation choices can materially affect immunogenicity and off-target effects.